The race to develop the best transcatheter mitral replacement valve technology continues to heat-up with Medtronic's $458m acquisition of Twelve, Inc.
Medtronic will pay $408m up-front for privately held Twelve, plus another $50m when a transcatheter mitral valve based on its technology earns a CE mark. Medtronic expects to close the deal in October and says the net impact from this transaction will be earnings neutral
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?